Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 2/20 | 0.72 |
| ▸ | SYK | P43405 | 4/20 | 0.57 |
| ▸ | BTK | Q06187 | 3/20 | 0.57 |
| ▸ | RAB9A | P51151 | 3/20 | 0.53 |
| ▸ | NPC1 | O15118 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | HPGD | P15428 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 5/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.49 |
| ▸ | MAPT | P10636 | 4/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | MAP4K4 | O95819 | 3/20 | 0.47 |
| ▸ | CLK2 | P49760 | 3/20 | 0.47 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.47 |
| ▸ | CLK4 | Q9HAZ1 | 3/20 | 0.47 |
| ▸ | SRPK1 | Q96SB4 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3898269 | 0.99 | KDR (0.70) | KDRSYKBTKRAB9ANPC1 | |
| SCHEMBL3891696 | 0.92 | KDR (0.66) | KDRSYKBTKRAB9ANPC1 | |
| SCHEMBL13867865 | 0.90 | KDR (0.72) | KDRSYKBTKRAB9ANPC1 | |
| SCHEMBL3892583 | 0.89 | KDR (0.69) | KDRSYKBTKRAB9ANPC1 | |
| SCHEMBL13867819 | 0.88 | KDR (0.68) | KDRSYKBTKRAB9ANPC1 | |
| SCHEMBL3903732 | 0.87 | KDR (0.73) | KDRSYKRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL3891347 | 0.87 | KDR (0.75) | KDRSYKRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL3901549 | 0.87 | KDR (0.60) | KDRSYKBTKRAB9ANPC1 | |
| SCHEMBL13867815 | 0.86 | KDR (0.66) | KDRSYKBTKRAB9ANPC1 | |
| SCHEMBL3889743 | 0.86 | KDR (0.64) | KDRSYKBTKRAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 148 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100074909-A1 | Combinations for the treatment of cancer | AMGEN INC (US) | 2010-03-25 | — | — | US | claimed |
| EP-1915151-A2 | COMBINATIONS FOR THE TREATMENT OF CANCER COMPRISING ANTI-EGFR ANTIBODY AND VEGFR INHIBITORS | Amgen, Inc (US) | 2008-04-30 | — | — | EP | claimed |
| WO-2006102504-A2 | COMBINATIONS FOR THE TREATMENT OF CANCER COMPRISING ANTI-EGFR ANTIBODY AND VEGFR INHIBITORS | AMGEN INC (US) | 2006-09-28 | — | — | WO | claimed |
| US-20060216288-A1 | Combinations for the treatment of cancer | AMGEN INC (US) | 2006-09-28 | — | — | US | claimed |
| US-7105682-B2 | Substituted amine derivatives and methods of use | AMGEN INC. (US) | 2006-09-12 | — | — | US | claimed |
| US-20030195230-A1 | Substituted amine derivatives and methods of use | AMGEN INC. | 2003-10-16 | — | — | US | claimed |
| EP-3170824-B1 | A 6-([1,2,4]TRIAZOLO[4,3-A]PYRIDIN-3-YLMETHYL)-1,6-NAPHTHYRIDIN-5(6H)-ONE DERIVATIVE AS C-MET INHIBITOR | AMGEN INC (US) | 2020-07-01 | — | — | EP | disclosed |
| EP-3330292-A1 | HUMAN C-FMS ANTIGEN BINDING PROTEINS | Amgen, Inc (US) | 2018-06-06 | — | — | EP | disclosed |
| US-9988457-B2 | Human C-FMS antigen binding proteins | AMGEN INC. (US) | 2018-06-05 | — | — | US | disclosed |
| EP-2188313-B1 | HUMAN C-FMS ANTIGEN BINDING PROTEINS | AMGEN INC (US) | 2017-11-01 | — | — | EP | disclosed |
| US-20170247459-A1 | COMBINATION THERAPY OF ANTIBODIES AGAINST HUMAN CSF-1R AND USES THEREOF | HOFFMANN-LA ROCHE INC. (US) | 2017-08-31 | — | — | US | disclosed |
| US-9745288-B2 | Compounds and methods for treating cancer by inhibiting the urokinase receptor | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2017-08-29 | — | — | US | disclosed |
| EP-2231663-B1 | 6-([1,2,4]TRIAZOLO[4,3-A]PYRIDIN-3-YLMETHYL)-1,6-NAPHTHYRIDIN-5(6H)-ONE DERIVATIVES AS C-MET INHIBITORS | AMGEN INC (US) | 2017-08-02 | — | — | EP | disclosed |
| US-20050118643-A1 | Specific binding agents to hepatocyte growth factor | AMGEN INC | 2005-06-02 | — | — | US | disclosed |
| WO-2005017107-A2 | SPECIFIC BINDING AGENTS TO HEPATOCYTE GROWTH FACTOR | AMGEN INC. (US) | 2005-02-24 | — | — | WO | disclosed |
| EP-1467721-A2 | SUBSTITUTED AMINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF ANGIOGENESIS | Amgen Inc. (US) | 2004-10-20 | — | — | EP | disclosed |
| WO-2004007481-A2 | SUBSTITUTED AMINE DERIVATIVES AND METHODS OF USE IN THE TREATMENT OF ANGIOGENESIS RELATES DISORDERS | AMGEN INC. (US) | 2004-01-22 | — | — | WO | disclosed |
| US-20030203922-A1 | Substituted amine derivatives and methods of use | AMGEN INC. | 2003-10-30 | — | — | US | disclosed |
| US-20030195230-A1 | Substituted amine derivatives and methods of use | AMGEN INC. | 2003-10-16 | — | — | US | disclosed |
| WO-2002068406-A2 | SUBSTITUTED AMINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF ANGIOGENESIS | AMGEN INC. (US) | 2002-09-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060216288-A1 | Combinations for the treatment of cancer | TP53, VHL, FOLR2 | KDR 2043/4885SYK 2698/4885BTK 2875/4885 |
| US-20030203922-A1 | Substituted amine derivatives and methods of use | MAOB, HNMT, FLT4 | KDR 13/4885SYK 678/4885BTK 768/4885 |
| US-20030195230-A1 | Substituted amine derivatives and methods of use | MAOB, HNMT, FLT4 | KDR 13/4885SYK 678/4885BTK 768/4885 |
| US-20100074909-A1 | Combinations for the treatment of cancer | TP53, VHL, FOLR2 | KDR 2043/4885SYK 2698/4885BTK 2875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.